A-Alpha Bio’s Post

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

In the continually advancing field of biologics, it's essential to search for new antibodies with distinct properties. The ability to screen primary B cells across diverse animal species broadens the diversity of recovered antibody sequences and increases the odds of finding the best antibody for any application across reagents, therapeutics, and basic health research. However, tapping into the antibody potential of these species has been challenging. In this Application Note, we outline how Bruker’s Opto® B Discovery portfolio on the Beacon® optofluidic system offers a new way to screen primary B cells from various species quickly. https://hubs.ly/Q02qjDhS0

Start you projects on the right foot with the best toolbox available to ensure a smooth process, from beginning to end, without the hindrance to be constantly transiently expressing your targets and dealing with the inherent high variability

Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #productmarketing

Join Promega and Evotec on September 24th for our upcoming webinar: Enabling High-Throughput Screening and Characterization of Targeted Protein Degraders with HiBiT Technology. Discover how HiBiT and NanoBRET technologies are advancing drug discovery by enabling efficient screening of degraders and detailed characterization of their cellular mechanisms. Gain insights into Evotec’s high-throughput platforms and workflows for identifying and characterizing these promising therapeutics. Visit the link to register and learn more: https://bit.ly/4d0xhnp

GeNext Genomics Introduces the a pinnacle in biologics innovation - our own Novel Antibody Clone Development. Tag along on the journey of discovery with our futuristic technology, meticulously tailored to craft novel antibody clones that redefine the boundaries of precision medicine. At GeNext Genomics, we don't just follow trends; we set them. Our Novel Antibody Clone Development empowers researchers and clinicians alike, offering bespoke solutions for diverse therapeutic needs. Partner with us at the forefront of scientific exploration and witness the transformation of possibilities in biologics. Usher in the New Era of Targeted Therapies with Us Today! . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #AntibodyClones #BiologicsInnovation 

🚀 Nanoclick: Pioneering receptor-mediated internalization Back to groundbreaking research on "Receptor-Mediated Internalization" presented by Viviana Gatta from UCB Biopharma at the Promega Innovation Days in Leuven. 🔬 Abstract: Cytosolic bioavailability limits the development of intracellular therapeutics. In contrast to small molecules, permeability of peptides across the plasma membrane is rarely achieved, and receptor-mediated internalization often leads to their degradation in the lysosomes. Nanoclick, a high-throughput and target-agnostic assay, combines click chemistry and Nano-Bret signal to directly quantify the amount of peptides or small molecules effectively reaching the cytosol. This method allows to optimize molecules based on their structure, activity and permeability, offering a flexible setup for various therapeutics and targets. 👏 Congratulations to Viviana Gatta and her team for this innovative work: Martine Geraerts (UCB), Noémie Willain (Novalix), Davide Proverbio (Novalix). 🤝 Insourcing, a unique collaborative model: Novalix partners with UCB Biopharma to provide discovery services on client’s site. This model fosters close collaboration, faster turnaround, and improved cost efficiency. ▶ Check out the full abstract and learn more about our innovative approaches in drug discovery: https://lnkd.in/e9pv2Rns #DrugDiscovery #Innovation #Nanoclick #Teamwork #Insourcing #Biopharma UCB

Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech

Time is running out: Register now for the 24th BioEquity Europe, May 12-14 in San Sebastian, Spain. Join more than 280 CEOs and 260 investors at this destination event for biopharma decision-makers. ✅ Register (don't wait, it will sell out): https://lnkd.in/gSxxhu7 One area to highlight: Half the 130 presenting biotechs are new to the BioEquity stage. If you are an investor or BD&L leader, BioEquity is where you meet newcos that have caught the eye of BioCentury Inc. (and my colleague Jeff Cranmer). A few examples: ➢ Alder Therapeutics ➢ Ananda Scientific ➢ BioCorteX ➢ Bloomsbury Genetic Therapies ➢ Cellaïon ➢ Cumulus Oncology ➢ Curadh MTR Inc ➢ Gate2Brain ➢ Kudo Biotechnology ➢ Kynos Therapeutics ➢ Laverock Therapeutics ➢ MitoRx Therapeutics ➢ Oniria Therapeutics ➢ Sapient Therapeutics ➢ Serna Bio ➢ TAUC3 BIOLOGICS ➢ Tessellate BIO ➢ Traverse Biotech, Inc ➢ and many more.... ✅ Visit the Presenting Company Dashboard to review their pipelines, financings, deals, and more: https://lnkd.in/ducEqTW3 Please send a DM if you have questions about the event. I hope to see you in San Sebastian! #biotech #biopharma #venturecapital #drugdevelopment #businessdevelopment #pharma #BioEquityEurope

PepTalk wrap up - 3 MAJOR Takeaways: 1️⃣ Complex Biologics are on the rise. Scientists are becoming more comfortable developing complex bispecific antibodies and advancing them into the clinic 🏥 2️⃣ AI is crucial for acceleration of antibody-based therapeutic development. But limited data on bispecifics specifically, being the limiting factor in this process. Most data still generated with IgG format. 💻 3️⃣ Personal observation: Antibody Engineering & Therapeutics Conference in December had more activity on the trade floor and, possibly at the sessions too. Either PepTalk is too early in the year or too undifferentiated from AET (and close in timing)⏱️ Bonus: despite that, I heard a lot of people attended PepTalk for the first time! 🎆 What were your biggest takeaways? #antibodydiscovery #chipeptalk #biotech #antibodies